These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 29162036)

  • 1. Sorafenib treatment for papillary thyroid carcinoma with diffuse lung metastases in a child with autism spectrum disorder: a case report.
    Higuchi Y; Motoki T; Ishida H; Kanamitsu K; Washio K; Oyama T; Noda T; Tsurumaru Y; Okada A; Tsukahara H; Shimada A
    BMC Cancer; 2017 Nov; 17(1):775. PubMed ID: 29162036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation.
    Iyer P; Mayer JL; Ewig JM
    Thyroid; 2014 Jan; 24(1):169-74. PubMed ID: 23544852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to Lenvatinib in Children with Papillary Thyroid Carcinoma.
    Mahajan P; Dawrant J; Kheradpour A; Quintanilla NM; Lopez ME; Orth RC; Athanassaki I; Venkatramani R
    Thyroid; 2018 Nov; 28(11):1450-1454. PubMed ID: 30226445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer.
    Danilovic DLS; Castro G; Roitberg FSR; Vanderlei FAB; Bonani FA; Freitas RMC; Coura-Filho GB; Camargo RY; Kulcsar MA; Marui S; Hoff AO
    Arch Endocrinol Metab; 2018 Jun; 62(3):370-375. PubMed ID: 29791660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.
    Gallo M; Michelon F; Castiglione A; Felicetti F; Viansone AA; Nervo A; Zichi C; Ciccone G; Piovesan A; Arvat E
    Endocrine; 2015 Aug; 49(3):726-34. PubMed ID: 25414068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy.
    Alzahrani AS; AlQaraawi A; Al Sohaibani F; Almanea H; Abalkhail H
    Thyroid; 2012 May; 22(5):536-41. PubMed ID: 22435913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with sorafenib in advanced thyroid cancer - a case report.
    Krajewska J; Olczyk T; Roskosz J; Paliczk-Cieślik E; Smietana AK; Kaczmarek-Borowska B; Jarząb B
    Endokrynol Pol; 2010; 61(5):492-6. PubMed ID: 21049464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The successful use of sorafenib to treat pediatric papillary thyroid carcinoma.
    Waguespack SG; Sherman SI; Williams MD; Clayman GL; Herzog CE
    Thyroid; 2009 Apr; 19(4):407-12. PubMed ID: 19355831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma.
    Chen L; Shen Y; Luo Q; Yu Y; Lu H; Zhu R
    Thyroid; 2011 Feb; 21(2):119-24. PubMed ID: 21186953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria.
    Goto H; Kiyota N; Otsuki N; Imamura Y; Chayahara N; Suto H; Nagatani Y; Toyoda M; Mukohara T; Nibu KI; Kasahara T; Ito Y; Miya A; Hirokawa M; Miyauchi A; Minami H
    Auris Nasus Larynx; 2018 Dec; 45(6):1249-1252. PubMed ID: 29779695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer.
    Toubert ME; Vercellino L; Faugeron I; Lussato D; Hindie E; Bousquet G
    Thyroid; 2011 Apr; 21(4):451-4. PubMed ID: 21385075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Off-label use of Sorafenib in patients with advanced thyroid carcinoma: Retrospective analysis of five cases.
    Bugalho MJ
    J Cancer Res Ther; 2016; 12(2):1084-7. PubMed ID: 27461704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
    Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.
    Worden F; Fassnacht M; Shi Y; Hadjieva T; Bonichon F; Gao M; Fugazzola L; Ando Y; Hasegawa Y; Park DJ; Shong YK; Smit JW; Chung J; Kappeler C; Meinhardt G; Schlumberger M; Brose MS
    Endocr Relat Cancer; 2015 Dec; 22(6):877-87. PubMed ID: 26370187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to sorafenib treatment in advanced metastatic thyroid cancer.
    Pitoia F
    Arq Bras Endocrinol Metabol; 2014 Feb; 58(1):37-41. PubMed ID: 24728162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful recovery from a subclavicular ulcer caused by lenvatinib for thyroid cancer: a case report.
    Kitamura M; Hayashi T; Suzuki C; Hirano S; Tateya I; Kishimoto Y; Omori K
    World J Surg Oncol; 2017 Jan; 15(1):24. PubMed ID: 28088233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy of lenvatinib for recurrent papillary thyroid carcinoma after multimodal treatment and management of complications: a case report.
    Tori M; Shimo T
    BMC Cancer; 2018 Jun; 18(1):698. PubMed ID: 29954369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer.
    Dadu R; Waguespack SG; Sherman SI; Hu MI; Busaidy NL; Jimenez C; Habra MA; Ying AK; Bassett RL; Cabanillas ME
    Oncologist; 2014 May; 19(5):477-82. PubMed ID: 24733667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib in the treatment of thyroid cancer.
    Ferrari SM; Politti U; Spisni R; Materazzi G; Baldini E; Ulisse S; Miccoli P; Antonelli A; Fallahi P
    Expert Rev Anticancer Ther; 2015; 15(8):863-74. PubMed ID: 26152651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
    Cabanillas ME; Waguespack SG; Bronstein Y; Williams MD; Feng L; Hernandez M; Lopez A; Sherman SI; Busaidy NL
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2588-95. PubMed ID: 20392874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.